It’s time to fix the staggering global inequities in access to COVID-19 vaccines, writes Gavin Yamey in a Nature commentary.
Reality Check: Wealthy countries have already bought up more than half of all global vaccine doses, though they account for just 16% of the world’s population, says the director of Duke University’s Center for Policy Impact in Global Health.
Yamey’s advice for rich countries:
- Stop the zero-sum game of buying up all available vaccines for your citizens, and apply a game theory approach. For example, negotiate deals with vaccine developers to share knowledge and technology to boost production by other manufacturers.
- Tithe the vaccine supply to poorer countries. For every 9 vaccines administered, donate 1 to the COVAX vaccine pool.
The Good News: COVAX, Yamey said at a Duke Global Health Institute media briefing yesterday, is “on course to do spectacular things by end of year”—potentially distributing 2 billion doses and getting all health workers and high risk people vaccinated.
The first COVAX vaccines landed in Ghana, according to Gavi—part of a flurry of promising developments on the vaccine front.
Vaccines: Good News, Bad News
Another shot: The FDA announced that Johnson & Johnson’s single-shot vaccine protects well against severe COVID-19 and may reduce the spread of the virus by vaccinated people, The New York Times reports. The vaccine could be authorized as early as Saturday and distribution could begin soon after.
A large real-world trial in Israel, published in The New England Journal of Medicine, found Pfizer/BioNTech's vaccine effective against symptomatic (~92% at 7 days post dose 2) and asymptomatic infections (~90%). However, the study didn’t test the vaccine’s efficacy on variants, which were rare in Israel when the study unfolded, MedPage Today notes.
Moderna and Pfizer/BioNTech are on the case: Both have variant-fighting boosters of their vaccines in the works and ready to begin clinical trials.
They’ll be needed. In less happy news, variants are proving formidable foes: